ph-797804
Small moleculeexperimental
Clinical trial activity
16 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
9
Phase 2
7
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2006 (NCT02084485)
Timeline
Indications
Mechanism of action
- MAP kinase p38 alphaINHIBITOR
MAPK14 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CNC(=O)c1ccc(C)c(-n2c(C)cc(OCc3ccc(F)cc3F)c(Br)c2=O)c1- Mol. weight
- 477.31 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1088751 ↗
Also known as
- ph797804
- ph797804
- ph797804
- ph 797804
- ph-797804
- ph-797804
- ph-797804
- ph-797804
- ph-797804
- pha-797804
- pha-797804
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01924650 | Phase 1 | Mar 1, 2014 | Pfizer |
| NCT01862887 | Phase 1 | Apr 1, 2013 | Pfizer |
| NCT01589614 | Phase 1 | Jun 1, 2012 | Pfizer |
| NCT01543919 | Phase 2 | Apr 1, 2012 | Pfizer |
| NCT01479647 | Phase 1 | Dec 1, 2011 | Pfizer |
| NCT01321463 | Phase 2 | May 1, 2011 | Pfizer |
| NCT01314885 | Phase 1 | Jan 1, 2011 | Pfizer |
| NCT01226693 | Phase 1 | Nov 1, 2010 | Pfizer |
| NCT01217918 | Phase 1 | Oct 1, 2010 | Pfizer |
| NCT01102660 | Phase 2 | May 1, 2010 | Pfizer |
| NCT00827515 | Phase 1 | Feb 1, 2009 | Pfizer |
| NCT00614705 | Phase 2 | Apr 1, 2008 | Pfizer |
| NCT00620685 | Phase 2 | Mar 1, 2008 | Pfizer |
| NCT00559910 | Phase 2 | Feb 1, 2008 | Pfizer |
| NCT00383188 | Phase 2 | Dec 1, 2006 | Pfizer |
| NCT02084485 | Phase 1 | Sep 1, 2006 | Pfizer |
Showing 16 of 16 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 16 | 16 | 2 | 2006 |
1 organizations
Page 1 / 1